GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Return-on-Tangible-Asset

Virax Biolabs Group (Virax Biolabs Group) Return-on-Tangible-Asset

: -71.48% (As of Sep. 2023)
View and export this data going back to 2022. Start your Free Trial

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Virax Biolabs Group's annualized Net Income for the quarter that ended in Sep. 2023 was $-5.82 Mil. Virax Biolabs Group's average total tangible assets for the quarter that ended in Sep. 2023 was $8.14 Mil. Therefore, Virax Biolabs Group's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2023 was -71.48%.

The historical rank and industry rank for Virax Biolabs Group's Return-on-Tangible-Asset or its related term are showing as below:

VRAX' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -3840.45   Med: -2576.82   Max: -96.24
Current: -96.24

During the past 4 years, Virax Biolabs Group's highest Return-on-Tangible-Asset was -96.24%. The lowest was -3840.45%. And the median was -2576.82%.

VRAX's Return-on-Tangible-Asset is ranked worse than
78.59% of 1555 companies
in the Biotechnology industry
Industry Median: -40.28 vs VRAX: -96.24

Virax Biolabs Group Return-on-Tangible-Asset Historical Data

The historical data trend for Virax Biolabs Group's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Return-on-Tangible-Asset
-3,086.96 -2,066.67 -3,840.45 -112.71

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Return-on-Tangible-Asset Premium Member Only Premium Member Only Premium Member Only -2,660.24 -5,026.09 -108.00 -107.52 -71.48

Competitive Comparison

For the Biotechnology subindustry, Virax Biolabs Group's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virax Biolabs Group Return-on-Tangible-Asset Distribution

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Return-on-Tangible-Asset falls into.



Virax Biolabs Group Return-on-Tangible-Asset Calculation

Virax Biolabs Group's annualized Return-on-Tangible-Asset for the fiscal year that ended in Mar. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=-5.457/( (0.049+9.634)/ 2 )
=-5.457/4.8415
=-112.71 %

Virax Biolabs Group's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Mar. 2023 )(Q: Sep. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Mar. 2023 )(Q: Sep. 2023 )
=-5.82/( (9.634+6.65)/ 2 )
=-5.82/8.142
=-71.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Sep. 2023) net income data.


Virax Biolabs Group  (NAS:VRAX) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Virax Biolabs Group Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Virax Biolabs Group (Virax Biolabs Group) Business Description

Traded in Other Exchanges
N/A
Address
20 North Audley Street, London, GBR, W1K 6LX
Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.